While whole abdominopelvic radiation (APRT) provided satisfactory radiation dosimetry for the treatment of cancers with peritoneal dissemination, APRT was abandoned due to unsatisfactory tumor control from necessary radiation shielding of vital organs. Our goal was to develop a helical tomotherapy (TOMO) abdominopelvic radiation technique improving target tissue coverage while dose-limiting vital organs, especially hematopoietic bone marrow. This study reports our clinical development of a TOMO abdominopelvic radiation technique for treatment of patients with advanced stage ovarian cancer. Novel chemoradiosensitizing agent clinical trials incorporating our TOMO abdominopelvic radiation technique for treatment of patients with recurrent ovarian cancer are under development.
Introduction
Tumoricidal abdominopelvic radiation for the treatment of cancer may also disrupt cell renewal vital to normal abdominal organ and hematopoietic function (1), promoting enteritis, reduced blood cell counts, nephritis and hepatitis. Women with epithelial ovarian cancers, at risk for surface shedding of tumor cells into the abdominal cavity, are occasionally treated with tumoricidal abdominopelvic radiation (2-12). Once given, abdominopelvic radiation may manifest in adverse radiation-related abdominal organ sequelae. Critically important in conventional abdominopelvic radiation for treatment of ovarian cancer is careful positioning of radiation beam stopping shields to protect radiation sensitive kidneys and liver. Therefore, while conventional abdominopelvic radiation sterilizes occult peritoneal sites of ovarian cancer, it may also result in compromised radiation dose delivery to peritoneal surfaces of the kidney and liver leading to early upper abdominal disease relapse.
Over the past two decades, two treatment strategies have been tested to lessen the incidence of ovarian cancer abdominopelvic relapse. A first approach has evaluated the clinical efficacy of intraperitoneal chemotherapy in the management of small-volume residual advanced ovarian cancer (13, 14) . Intraperitoneal chemotherapy clinical trials have been met with remarkable improvements in disease-free survival, with manageable posttherapy nausea, vomiting, renal disturbances, abdominal distention, and catheter-related complications (15, 16) . A second approach involves change in technique of radiation dose delivery. Here, limitations of crude radiation shielding in early years and the use of shrinking radiation treatment portal techniques have been replaced by more sophisticated radiation dose sculpting by beam collimation (7) (8) (9) and by more suitable large field radiation techniques such as helical tomotherapy (10-12).
Our case series hypothesizes that helical tomotherapy abdominopelvic radiation better delivers therapeutic radiation to peritoneal surfaces while simultaneously dose-limiting critical organs at risk as compared to conventional abdominopelvic radiation. Design, assignment, and implementation of planned tomotherapy abdominopelvic dose avoidance structures and priorities are provided.
Materials and Methods

Patients
In this retrospective study, we identified four women aged 48, 55, 58, and 64 years who were diagnosed with recurrent stage 3 platinum-resistant epithelial ovarian cancer and who were treated by abdominopelvic radiation for abdominal relapse of disease. All four women had undergone prior maximal safe tumor debulking hysterectomy and had received platinumand taxane-based chemotherapy (Table I) . Although not considered an exclusion criterion for abdominopelvic radiation, no patient received intraperitoneal chemotherapy.
Two women (patients #1 and #2) received conventional abdominopelvic radiation to a dose of 30 Gy in 1.5 Gy daily fractions using 18 megavoltage (MV) photons delivered by a conventional radiation treatment system (Varian 2100C, Varian Medical System Inc., Palo Alto, CA, USA). Both women provided informed written consent for abdominopelvic radiation treatment. With institutional review board approval, we undertook a retrospective comparative analysis of a treated conventional abdominopelvic radiation dosimetry plan and a non-treated tomotherapy radiation dosimetry plan.
Two women (patients #3 and #4) received helical tomotherapy abdominopelvic radiation delivered by 6 MV photons (Tomotherapy, Inc., Madison, WI). Patient #3 received a dose of 21 Gy in 1.5 Gy daily fractions and patient #4 received a dose of 30.1 Gy in 2.15 Gy daily fractions arbitrarily chosen given their prior chemoradiation therapies and patientdesired goals of therapy (Table I) . With institutional review board approval, we assessed tomotherapy abdominopelvic dosimetry and acute ,30 day toxicity outcomes assessed by common terminology criteria for adverse events version 4.0.
Conventional Abdominopelvic Radiation
For patients #1 and #2, treatment planning computed tomography (CT) images were acquired at a uniform 3 millimeter slice thickness on a Philips AcQsim scanner (Philips Healthcare, Richmond Heights, OH, USA). Each woman was scanned supine from the mid-thoracic cavity through the lesser trochanter of the femur on a carbon fiber board (MED-TEC, Orange City, IA, USA) during shallow breathing. Indexed torso immobilization involved a knee pad overlying an EXACT two-pin localization bar (MED-TEC) secured to the carbon fiber board. Arms were positioned comfortably folded over the chest. Using a Pinnacle 3 radiation planning computer workstation and digital reconstructed radiographs of the abdomen and pelvis, physicians identified the entire abdominal cavity as the clinical target volume of interest. A planning target volume was generated and included a superior 15 millimeter margin on the clinical target volume and seven millimeter margin inferiorly and laterally to allow for set-up error. The dosimetric isocenter for conventional abdominopelvic radiation was located midway between the diaphragm and bilateral obturator foramina. Anteroposterior (AP) and posteroanterior (PA) radiation treatment fields were planned using an extended source-to-axis distance of 120 centimeters. The AP/PA field borders spanned 15 millimeters superior to the diaphragm at maximal exhalation and 10 millimeters inferior to the bilateral obturator foramina (17). Lateral AP/PA field borders flashed the skin. Customized cerrobend beam blocks providing a 10 millimeter margin on each kidney were added to the PA beam to reduce radiation dose. No multileaf collimation was used. Prior to treatment, laser triangulation was done to align the torso. Contoured organs at risk included the entire liver, bilateral kidneys, and bone marrowbearing abdominopelvic bones (i.e., mid-thoracic to lumbar vertebral bodies, sacrum and pelvis, and bilateral proximal femora to the lesser trochanter).
Helical Tomotherapy Abdominopelvic Radiation
For comparison to conventional abdominopelvic radiation only in patients #1 and #2, and for treatment in patients #3 and #4, helical tomotherapy plans were generated using treatment planning CT images and patient positioning as described above for conventional abdominopelvic radiation. Physicians contoured a clinical target volume of the entire abdominal cavity using the Hi-Art Tomotherapy Treatment Planning Station (Tomotherapy, Inc., Madison, WI). Contoured organs at risk included the liver, bilateral kidneys, and abdominopelvic bones as above. The liver was contoured in its entirety and assigned a dose percent constraint, overlap priority, and importance with the intent of a 0.3 cm peripheral ring of liver surface permitted to receive the prescription dose ( Figure 1 , Table II) . A kidney dosimetric avoidance ring was created by outlining a 0.5 cm peripheral ring around each right and left kidney (Figure 1 ). The volume of tissue in the kidney avoidance ring was subtracted from the clinical target volume during tomotherapy plan optimization. Radiation dose within the kidney avoidance ring was later added back to the clinical target volume when assessing radiation dose coverage. Bone marrow-bearing abdominopelvic bones in their entirety were contoured as an avoidance structure (Figure 1 ). Prior to tomotherapy plan optimization, the abdominal cavity clinical target volume and critical OARs were allocated radiation dose constraints, target/organ overlap priority, and importance factors (Table II) . Radiation dose and delivery parameters (5 cm jaw, 0.3 cm pitch, normal grid width, and a 1.96 modulation factor) were determined utilizing a convolution superposition approach. At least 95% of the abdominal cavity planning tumor volume was to receive the radiation prescription dose.
Statistics
No statistical endpoints were analyzed because of small sample sizes.
Results
Conventional and Helical Tomotherapy Dosimetry Comparison
Figure 1 depicts representative radiation dose distribution for conventional and helical tomotherapy abdominopelvic radiation, with particular attention to representative dosimetry within the liver and bilateral kidneys. These Figures illustrate superior target coverage of the abdominal cavity with minimal dose spillage to the liver and kidneys by tomotherapy, as compared to conventional radiation. For the two women treated by conventional radiation (patient #1 and patient #2), 72.5% and 66.5% of the targeted abdominopelvic cavity received the 30 Gy prescription dose. Tomotherapy target coverage predicted for the same target volumes were 95.0% and 95.1%, comparing favorably to dose constraints applied to conventional radiation (Table II) (18, 19) . Radiation beam-on treatment times were 0.8 and 0.8 minutes for conventional radiation, and were estimated at 8.9 and 9.5 minutes respectively for tomotherapy treatment. This did not include set-up time.
The dosimetric radiation dose advantages provided by tomotherapy are best shown in target coverage around the bilateral kidneys. During tomotherapy treatment, a patient slides slowly and continuously through the tomotherapy rotational bore, where a rotational gantry mounted with a 6 MV linear accelerator delivers megavoltage photons at an 85 cm source-to-axis distance. As radiation is delivered, 64 binary tungsten leaf collimators allow tomotherapy to sculpt precisely radiation dose around targeted and non-targeted tissues. In this way, the peripheral peritoneal surfaces of the bilateral kidneys achieve a clinically relevant radiation dose with tomotherapy, as compared to a reduced anterior kidney peritoneal dose from conventional radiation due to the posterior kidney blocks (Figure 1) . Again with the design features of tomotherapy, peritoneal surfaces of the liver potentially harboring occult tumor receive tumoricidal radiation doses, but estimates for central inner liver radiation dose are substantially lower with tomotherapy. With conventional radiation, the liver receives nearly full radiation prescription doses (Figure 1) . Also, tomotherapy affords high priority radiation dose avoidance to the thoracolumbar vertebrae and pelvic bones sparing bone marrow at risk for radiation-related suppression of hematopoietic cell renewal. Conventional abdominopelvic radiation doses marrow-harboring bones to full radiation dose (Figure 1 ).
Composite radiation dose volume histograms for conventional and tomotherapy radiation provide favorable support for tomotherapy abdominopelvic treatment through reduction of normal organ radiation dose (Figure 2 ). The volume of the liver receiving a radiation dose constraint of 30 Gy (18) was 59.0% and 84.6% for conventional radiation and estimated at 6.9% and 8.0% respectively for tomotherapy radiation. Likewise, the volume of the kidney receiving at least 15 Gy (19) was 66.7% and 82.3% for conventional radiation versus 38.6% and 40.2% respectively for tomotherapy radiation. The entire peritoneal surfaces of the bowel, deemed targets for radiation therapy, received the prescription dose of 30 Gy either by a conventional or by tomotherapy radiation technique.
Large-field irradiation is often associated with low dose radiation spillage to large volumes of body tissue. Cumulative body tissue radiation doses exceeding 4 Gy may be associated with marrow aplasia (20, 21), lowering circulating mature granulocytes, platelets, and erythrocytes in the blood. Irradiation of vertebral and pelvic bones harboring hematopoietic stem cells may suppress circulating blood cells, but there may also be compensatory hematopoietic stem cell stimulation in unirradiated bones obscuring measurement of radiation effect. Data suggest that hematopoietic stem cell irradiation of 20 Gy corresponds to clinicallyevident marrow aplasia (22). In our dosimetric comparison, we found that conventional abdominopelvic radiation in these two women led to 78.0% and 73.2% of vertebral and pelvic bone marrow receiving at least 20 Gy radiation dose. By contrast, tomotherapy treatment predicted 38.9% and 38.5% of vertebral and pelvic bone marrow respectively receiving at least a 20 Gy radiation dose.
Helical Tomotherapy Radiation Treatment
Given her prior chemotherapy and radiation treatments (Table I) , patient #3 elected helical tomotherapy radiation for treatment of left lower abdominal cavity disease progression associated with painful malignant ascites requiring every week abdominocentesis. An abdominal cavity volume of 12,531.8 cm 3 received 21 Gy in 14 fraction of 1.5 Gy prescribed to the 100% isodose line to achieve 95.0% abdominopelvic target coverage. The volume of liver receiving 30 Gy, of kidney receiving 15 Gy, and vertebral and pelvic bone marrow receiving 20 Gy were 0%, 35.2%, and 5.2%, respectively. The bowel received 100% of the prescription dose of 21 Gy. During her fractionated tomotherapy course, no significant grade 2 or higher skin, urinary, or gastrointestinal toxicities were encountered. One week into tomotherapy abdominopelvic radiation, she no longer underwent abdominocentesis and was free of abdominal pain. At last follow-up six weeks after abdominopelvic radiation, she remained symptom-free with no need for abdominocentesis.
Given her refusal for further chemotherapy and pretreatment history of radiation (Table I) , patient #4 elected helical tomotherapy radiation for treatment of diffuse abdominal cavity disease progression associated with nausea-inducing malignant ascites requiring every other week abdominocentesis. An abdominal cavity volume of 8,820.2 cm 3 received 30.1 Gy in 14 fractions of 2.15 Gy prescribed to the 100% isodose line to achieve 95.4% target abdominopelvic coverage. 3.9% of the liver volume received 30 Gy or more, 16.2% of the kidney volume received 15 Gy or more, and 49.9% of vertebral and pelvic bone marrow received at least 20 Gy. The bowel received 100% of the prescription dose of 30.1 Gy. During her fractionated tomotherapy course, no significant grade 2 or higher skin or urinary toxicities were encountered. The patient was hospitalized for four days after the last abdominopelvic radiation treatment for symptomatic grade 2 diarrhea and grade 3 nausea with dehydration. With intravenous fluids and anti-emetic therapy, she recovered. Abdominocentesis was no longer done two weeks into her tomotherapy abdominopelvic radiation. At last follow-up four weeks after completion of abdominopelvic radiation, she remained symptom-free and with no need for abdominocentesis. 
Discussion
The evidence in this study suggests that helical tomotherapy abdominopelvic radiation provides superior target coverage while simultaneously dose-limiting critical organs at risk when compared to conventional abdominopelvic radiation. Tomotherapy treatment potentially provides improved radiation dose coverage of peritoneal surfaces, especially near the kidney and liver because of not needing protective kidney and liver blocks required during conventional radiation. Tomotherapy treatment also provides lower radiation dose delivery to the liver, bilateral kidneys, and skeletal bone harboring bone marrow.
While tomotherapy has improved dose targeting of the abdominal cavity and dose reduction of critical visceral organs and bone marrow, tomotherapy nevertheless imposes challenges for radiation oncologists and medical dosimetrists. Observational studies have suggested that human oocytes and supporting epithelial ovarian cells are exquisitely sensitive to radiation, with an estimated radiation dose of 2 to 6 Gy needed to sterilize cells (23, 24) . As such, abdominopelvic radiation doses between 20 to 30 Gy produced robust response rates of 50 to 70 percent in ovarian cancer cells (2) (3) (4) (5) (6) . And yet, abdominopelvic radiation use dwindles due to a perceived lack of efficacy and high toxicity (25) (26) (27) . No current clinical trials are in progress evaluating the effectiveness of platinumbased multiagent chemotherapy versus abdominopelvic radiation. However, roles for abdominopelvic radiation in the management of small-volume residual advanced ovarian cancer and in the sensitization of administered chemotherapy are emerging. In one clinical trial conducted by the SwedishNorwegian Ovarian Cancer Study Group (6) women with ovarian cancer underwent debulking extirpative surgery to less than two centimeters of disease and platinum-based chemotherapy followed by randomization either to no further treatment, more chemotherapy, or abdominopelvic radiation after a complete chemotherapy response, or to more chemotherapy or abdominopelvic radiation after a partial chemotherapy response. In both groups, ovarian cancer disease-free survival was superior after abdominopelvic radiation. In a second clinical study, the Gynecological Oncology Group used low dose (i.e., 60-80 cGy) abdominopelvic radiation fractionated twice daily to enhance the sensitivity of ovarian and peritoneal cancers to the antitumor effect of docetaxel. This study found that abdominopelvic radiation given with docetaxel chemotherapy was safe, well-tolerated, and warranted further clinical study (17).
One alternative treatment modality to improve target coverage while reducing normal tissue radiation is intensity modulated radiation therapy (IMRT). IMRT treatment applies non-uniform photon fluence among multiple angled radiation treatment beams to produce relative high-dose radiation in targeted tissues at the cost of exposing more intervening tissues to low radiation doses (7-9). Extended radiation beam field lengths often .40 centimeters, multiple dose isocenters in the abdomen and pelvis, and treatment complexity all limit widespread practicality (7-9). Comparatively, helical tomotherapy treatment obviates extended beam field lengths and multiple dose isocenters due its continuous helical delivery of radiation. Another advantage of abdominopelvic tomotherapy is that it provides improved radiation dose homogeneity with high priority radiation dose avoidance to critical organs at risk. As such, radiation dose "hot spots" common within bowel following conventional abdominopelvic radiation are avoided, lessening the risk of long-term bowel sequelae. Our findings are in accord with other studies of tomotherapy for abdominopelvic radiation (10-12). Introduced new in this study are recommended target/organ overlap priority and importance factors (Table II) . Also new are novel tomotherapy dosimetry planning optimization liver, kidney and marrow radiation dose avoidance structures that allow dosing of peritoneal surfaces and that protect critical organs from excessive irradiation (Figures 1 and 2 ).
This study would be strengthened by a larger, treated patient population. Other case series have demonstrated technical feasibility and efficacy of tomotherapy abdominopelvic radiation, and thus, argue for further investigative study of this technique in the management of epithelial ovarian and abdominal cancers (10-12). Larger, long-term data sets are needed to fully capture the impact of tomotherapy upon reducing treatment-related sequelae. For instance, in our study evaluation of dose-volume relationships for the entire lung was not recoverable due to CT-based planning that only captured the lung bases. Future studies of the helical tomotherapy abdominopelvic radiation technique should incorporate this important relationship given a perceived risk for radiation pneumonitis. Even though our primary aim was to describe therapeutic abdominopelvic radiation delivery using helical tomotherapy, we did treat two patients with our tomotherapy technique albeit with radiation dose varying due to constraints of pretreatment chemotherapy and radiation and patient desired treatment goals. Both patients tolerated treatment well and had symptom relief. While this study cannot provide comment on whether abdominal organ toxicity will be averted fully in patients treated by abdominopelvic tomotherapy radiation, our findings do suggest that the technique is feasible and well-tolerated. Our research group plans phase 1 clinical trials of novel chemoradiation anticancer agents and abdominopelvic radiation delivered by helical tomotherapy.
In conclusion, our study showed that tomotherapy treatment provides improved abdominopelvic peritoneal surface radiation dose while avoiding critical organs at risk.
